Overview

A Study of BMS-863233 in Patients With Hematologic Cancer

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Exelixis